NRXP
HealthcareNRx Pharmaceuticals, Inc.
$2.41
$-0.21 (-8.02%)
Jan 5, 2026
Price History (1Y)
Analysis
NRx Pharmaceuticals, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $71.35 million. The company's revenue for the trailing twelve months (TTM) was $242,000. The financial health of NRx Pharmaceuticals is characterized by significant losses, as evidenced by its net income and EBITDA figures. Specifically, the company reported a net loss of $38,060,000 and an EBITDA loss of $15,199,000 for the TTM period. Additionally, the company's operating margin was -1701.7%, indicating substantial operational expenses relative to revenue. The balance sheet shows that NRx Pharmaceuticals has $10.26 million in debt and $7.18 million in cash. The valuation context of NRx Pharmaceuticals is notable for its low price-to-book ratio (-2.59) and negative EV/EBITDA (-5.05). While the company's forward P/E ratio is 18.54, it does not provide a clear indication of its growth prospects or earnings potential. Furthermore, the company does not pay dividends, as reflected in its zero payout ratio.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Visit website →Key Statistics
- Market Cap
- $71.35M
- P/E Ratio
- N/A
- 52-Week High
- $6.01
- 52-Week Low
- $1.58
- Avg Volume
- 485.06K
- Beta
- 1.62
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States